Skip to main
GILD

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 47%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences demonstrates a positive financial outlook driven by increased demand and share gains, particularly highlighted by Biktarvy's significant rise to 52% market share in the US, up from 49% in the prior quarter. The company has also provided upward adjustments to its HIV growth guidance, now projecting a year-over-year increase of 5%, despite facing notable Medicare Part D headwinds. Strengthening its diversified portfolio, Gilead's ongoing integration of innovative therapies in oncology and its effective life-cycle management strategy further enhances the potential for sustained revenue growth and market position.

Bears say

Gilead Sciences is experiencing significant challenges across its product portfolio, particularly in the oncology segment, with projected cell therapy sales anticipated to decline by approximately 10% year-over-year in 2025, suggesting ongoing competitive pressures. Additionally, revenue from Veklury has seen a substantial decrease of 60% year-over-year, leading Gilead to lower its FY25 revenue guidance for the drug due to diminishing COVID-19 related hospitalizations and competition. The overall performance in key therapeutic areas, including a 11% year-over-year decline in cell therapy revenues, raises concerns about Gilead's growth prospects and its ability to maintain a robust financial outlook in the near term.

Gilead Sciences (GILD) has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 47% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 19 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $126.68, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $126.68, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.